Related Experiment Video
Updated: Mar 16, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
[ANTENATAL APPLICATION OF CORTICOSTEROIDS IN LATE PRETERM BIRTHS]
Insights
Antenatal corticosteroid therapy is recommended for women at risk of premature birth. However, its benefits after 34 weeks of gestation remain under discussion.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Medicine
- Pharmacology
Context:
- Premature birth presents significant risks to neonates.
- Antenatal corticosteroid (ACS) administration is a key intervention to improve neonatal outcomes.
- Evidence regarding the efficacy and safety of ACS after 34 weeks of gestation is evolving.
Purpose:
- To review and synthesize current evidence on the antenatal use of corticosteroids in the context of premature birth.
- To critically evaluate the benefits and risks of corticosteroid administration between 34 and 37 weeks of gestation.
- To inform clinical practice guidelines and future research directions.
Summary:
- Current evidence supports the use of antenatal corticosteroids for women at risk of preterm birth before 34 weeks gestation.
- The benefits of antenatal corticosteroids in women at risk of preterm birth after 34 weeks gestation are less clear and subject to ongoing debate.
- Further research is needed to establish optimal timing and protocols for corticosteroid use in late preterm infants.
Impact:
- Provides a comprehensive overview of the current evidence base for antenatal corticosteroid use.
- Highlights areas of uncertainty and controversy, particularly for late preterm births.
- Aims to guide clinical decision-making and resource allocation in perinatal care.
Abstract:
The aim of the following study is to present the current evidence of antenatal use of corticoids in premature birth. The benefits of antenatal use of corticosteroids after 34 week of gestation is still a process of discussion.
Related Concept Videos
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Teratogenicity
COPD: Management Using Bronchodilators and Corticosteroids
Intrauterine Drug Delivery Systems

